checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


OTEZLA significantly improves
skin plaques1

Response was maintained with OTEZLA through
week 321

 

SIGNIFICANTLY MORE PATIENTS ACHIEVED PASI-75
VS PLACEBO1,a,b

significantly more patients achieved pasi-75 results versus placebo in a clinical trial
a

ESTEEM® 1 study. Full analysis set, LOCF.

b

P < 0.0001.

ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index.

Reference: 1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015. 


Select an e-mail client to share

close x